Compare FTCI & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTCI | GRML |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 29.2M |
| IPO Year | 2021 | 2022 |
| Metric | FTCI | GRML |
|---|---|---|
| Price | $1.90 | $5.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | 459.3K | ★ 17.3M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $33.71 | N/A |
| Revenue Next Year | $51.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $1.83 | $0.16 |
| 52 Week High | $12.75 | $18.21 |
| Indicator | FTCI | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 44.17 |
| Support Level | N/A | $0.60 |
| Resistance Level | $2.78 | $11.66 |
| Average True Range (ATR) | 0.23 | 2.64 |
| MACD | -0.03 | -0.82 |
| Stochastic Oscillator | 7.05 | 0.60 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S.-manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.